Results 161 to 170 of about 15,160 (239)

Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2280-2291, November 2026.
Objective Proteome‐wide risk models for lupus remain underexplored. We developed classification models to identify lupus from serum proteomic profiles. Methods Patients with lupus and individuals with other autoimmune diseases in the UK Biobank were included.
Mehmet Hocaoǧlu   +2 more
wiley   +1 more source

Role of selectins and their receptors in the regulation of the haemopoietic system

open access: yes
The production of blood cells occurs in the bone marrow. This process depends on the controlled proliferation and development of rare and multipotent precursors called haemopoietic stem cells, and involves a subtle balance between the positive regulation

core  

Posttranslational Modification Cross‐Talk in Vascular Cells: Molecular Mechanisms and Therapeutic Implications for Atherosclerosis

open access: yesCell Biochemistry and Function, Volume 44, Issue 11, November 2026.
ABSTRACT Atherosclerosis is driven by coordinated changes in endothelial cells (ECs), macrophages, and vascular smooth muscle cells (VSMCs). Post‐translational modifications (PTMs), phosphorylation, acetylation, ubiquitination, SUMOylation, O‐GlcNAcylation, palmitoylation, ISGylation, and ADP‐ribosylation, integrate metabolic, inflammatory, and ...
Weiwei Jiang, Haiping Du
wiley   +1 more source

Anti‐Inflammatory Therapies in Coronary Artery Disease; A Systematic Review

open access: yesClinical Cardiology, Volume 49, Issue 11, November 2026.
This review explores the evidence for anti‐inflammatory medications in prevention of MACE, effects on radiographic measurements of coronary disease, and prevention of reperfusion injury when administered in the acute setting. Of particular note are the trials concerning medications targeting the NLRP3 inflammasome pathway and its downstream products ...
Louis de Courcy, Jack Moore
wiley   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1301-1314, November 2026.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović   +11 more
wiley   +1 more source

From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer. [PDF]

open access: yesChem Rev
Aasted MKM   +5 more
europepmc   +1 more source

Hesperidin as a Multi‐Target Phytochemical: Therapeutic Applications, Medicinal Chemistry Insights, and Advances in Synthetic Analogs

open access: yesFood Frontiers, Volume 7, Issue 6, November 2026.
This review offers a thorough examination of the therapeutic uses of hesperidin, emphasizes significant findings from structure‐activity relationship research, and addresses recent advancements in the synthesis and biological assessment of hesperidin analogs.
Mohammadsaeed Kordi   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy